Last reviewed · How we verify
NA therapy
NA therapy works by removing or inactivating the abnormal red blood cells in the body.
NA therapy works by removing or inactivating the abnormal red blood cells in the body. Used for Hemolytic anemia.
At a glance
| Generic name | NA therapy |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
NA therapy is a process that involves removing or inactivating the abnormal red blood cells in the body. This is typically done through apheresis, a procedure that separates the blood into its different components and removes the abnormal red blood cells. The remaining blood components are then returned to the body.
Approved indications
- Hemolytic anemia
Common side effects
- Allergic reactions
- Bleeding
- Infection
Key clinical trials
- Strategy for Unstable Coronary Plaque in Patients Presenting to Emergency Department for Chest Pain Suspected of Coronary Artery Disease (NA)
- Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection (PHASE2)
- Integrated Treatment for Enhancing Growth in Recovery During Adolescence (NA)
- A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy (PHASE1)
- Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection (PHASE1, PHASE2)
- Family-focused vs. Drinker-focused Smartphone Interventions to Reduce Drinking-related Consequences of COVID-19 (NA)
- Multidimensional Frailty Assessment and Post-Transplant Outcomes in Liver Transplant Candidates
- Contribution of Bone to Urine Citrate
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NA therapy CI brief — competitive landscape report
- NA therapy updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI